Back to results
US 12,600,965 B2Granted
Modified double stranded oligonucleotide
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsDonald Foster, Mark K. Schlegel, Christopher Brown
Life of this patent
Estimating the term…
Abstract
One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
Claims38
A dsRNA agent comprising:
- a sense strand having a length of 17-35 nucleotides;
- an antisense strand having a length of 17-35 nucleotides;
- at least two phosphorothioate internucleotide linkages between the first five nucleotides of the antisense strand, counting from the 5′ end of the antisense strand;
- and
- only three, four, five or six 2′-deoxy modifications on the antisense strand;
- wherein:
- at least two 2′-deoxy modifications are in a central region of the sense strand, wherein the central region of the sense strand is positions 7, 8, 9, 10, 11, 12, and 13 counting from the 5′-end of the sense strand;
- three of the 2′-deoxy modifications of the antisense strand are at positions 2, 12, and 14, counting from the 5′-end of the antisense strand;
- the sense strand and the antisense strand form a duplex region containing between 17 to 25 base pairs;
- the dsRNA agent comprises a ligand;
- the sense strand does not comprise a glycol nucleic acid (GNA);
- and
- the 2′-deoxy modifications are not 2′-deoxy-2′-fluoro (2′-F) nucleoside.
10 more elements
Dependencies are inferred from the claim text.